ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Delivery Strategies for Oncolytic Viruses in Gastrointestinal Cancers: Progress, Mechanisms and Clinical Translations.Reviews in medical virology · 2026Review
- Advances in oncolytic virus delivery strategies and challenges in clinical translation.Materials today. Bio · 2026Review
- Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology · 2026Review
- Mathematical Modeling of the Role of Cytokines in Sindbis Virus Treatment of Glioblastoma.CPT: pharmacometrics & systems pharmacology · 2026Article
- Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.Lancet (London, England) · 2025Review
- Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges.Seminars in immunology · 2025Review
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.Journal of hematology & oncology · 2025Article
- Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.Journal for immunotherapy of cancer · 2024Article
- Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.Cancer immunology research · 2024Article
- Construction and application of adenoviral vectors.Molecular therapy. Nucleic acids · 2023Review
- Joining Forces: The Combined Application of Therapeutic Viruses and Nanomaterials in Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- Investigating the potential of oncolytic viruses for cancer treatment via MSC delivery.Cell communication and signaling : CCS · 2023Review
- Article
- Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma.Frontiers in immunology · 2023Review
- Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes.Communications biology · 2022Article
- Clinical advances in oncolytic virotherapy for pediatric brain tumors.Pharmacology & therapeutics · 2022Review
- Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?Molecular therapy oncolytics · 2022Review
- Review
- Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.Journal for immunotherapy of cancer · 2021Article
- Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.Journal for immunotherapy of cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Optimum clinical protocols require systemic delivery of oncolytic viruses in the presence of an intact immune system. We show that preconditioning with immune modulators, or loading virus onto carrier cells ex vivo, enhances virus-mediated antitumor activity. Our early trials of systemic reovirus delivery showed that after infusion reovirus could be recovered from blood cells--but not from plasma--suggesting that rapid association with blood cells may protect virus from neutralizing antibody. We therefore postulated that stimulation of potential carrier cells directly in vivo before intravenous viral delivery would enhance delivery of cell-associated virus to tumor. We show that mobilization of the CD11b(+) cell compartment by granulocyte macrophage-colony stimulating factor immediately before intravenous reovirus, eliminated detectable tumor in mice with small B16 melanomas, and achieved highly significant therapy in mice bearing well-established tumors. Unexpectedly, cytokine conditioning therapy was most effective in the presence of preexisting neutralizing antibody. Consistent with this, reovirus bound by neutralizing antibody effectively accessed monocytes/macrophages and was handed off to tumor cells. Thus, preconditioning with cytokine stimulated recipient cells in vivo for enhanced viral delivery to tumors. Moreover, preexisting neutralizing antibody to an oncolytic virus may, therefore, even be exploited for systemic delivery to tumors in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.